Feldan Therapeutic has closed an additional Series B round of financing, raising $[mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT – where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. Be informed!#[/mepr-active][mepr-active rule=”374″]3,066,747 from 45 Quebec based investors through the issuance of 15,478,21 Class B Preferred shares priced at $0.1589. Clot Adocats Inc. acted as legal counsel.[/mepr-active]
Quebec City based Feldan Therapeutic is dedicated to the development of regenerative medicine therapeutic applications based on the Feldan Shuttle platform, a breakthrough peptide-based delivery method that allows the introduction of foreign proteins inside cells.
Feldan Therapeutic has previously raised $[mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT – where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. Be informed!#[/mepr-active][mepr-active rule=”374″]6.5[/mepr-active] million in seven rounds of financing from members of Anges Québec, Anges Québec Capital Fund and FIER Succès.